Saturday 17 October 2026
Export NBP’s income statement to Excel — free account
NovaBridge Biosciences
In the quarter to June 2026, EPS fell 123.3% and free cash flow grew 34.3%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
1.26
0.03
−2.33%
Follow NBP
| Older periods | Mar '25 | Jun '25 | Sep '25 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(4.12%) | (18.46%) | 0.00% | 0.00% | |
| (2.61%) | (17.37%) | 0.00% | 0.00% | ||
ROIC |
(101.34%) | (76.65%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(5.47%) | (24.92%) | 0.00% | 0.00% | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
0.00 | (1.39) | 0.00 | 0.00 | |
Free Cash Flow |
— | (113.36) | (108.70) | (92.64) | |
Capital Expenditures |
— | (2.71) | 0.11 | (1.04) | |
| Other line items | |||||
Cash ROIC |
0.00% | (31.29%) | (22.31%) | (23.64%) | |
Tax Rate |
0.00 | 0.00 | — | — | |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | — | — | |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.00 | 2.77 | 0.00 | 0.00 | |
Depreciation/Fixed assets |
0.00 | 11.46 | 10.32 | 1.29 | |
Capex/Depreciation |
— | (1.38) | 0.07 | (0.64) | |
Revenue per Share |
0.00 | 0.00 | — | — | |
Operating CF per Share |
0.00 | (1.35) | 0.00 | 0.00 | |
Capex per Share |
0.00 | (0.03) | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 1 Oct 2026